PAREXEL International Corporation (PRXL) : The total negative money flow of $1.44 million on Thursday indicates selling on strength. The inflow of money on upticks was $5.5 million, compared to $6.94 million outflow on downticks, which confirms distribution in the stock. The up to down ratio was 0.79. The negative money flow of $1.59 million in block trades reveals that the informed traders sold the stock on every bit of price strength.The transaction value of block trade on downtick was $1.59 million. The price action in the PAREXEL International Corporation (PRXL) stock suggests that both the bulls and the bears were in equilibrium. The stock traded at $63.71 with a gain of $0.24 , a change of 0.38% over the previous days close. The stock registered 0.38% for the week.
PAREXEL International Corporation (PRXL) : Average target price received by PAREXEL International Corporation (PRXL) is $66 with an expected standard deviation of $8.21. The most aggressive target on the stock is $73, whereas the most downbeat target is $49. 7 financial analysts are currently covering the stock. The stock has recorded a 20-day Moving Average of 6.76% and the 50-Day Moving Average is 6.11%.
PAREXEL International Corporation (NASDAQ:PRXL): During Thursdays trading session, Bulls were in full control of the stock right from the opening. The stock opened at $63.76 and $63.29 proved to be the low of the day. Continuous buying at higher levels pushed the stock towards an intraday high of $64.36. The buying momentum continued till the end and the stock did not give up its gains. It closed at $64.27, notching a gain of 1.26% for the day. The total traded volume was 570,703 . The stock had closed at $63.47 on the previous day.
PAREXEL International Corporation (PAREXEL) is a biopharmaceutical outsourcing services company, which provides a range of expertise in clinical research, clinical logistics, medical communications, consulting, commercialization, and advanced technology products and services to the pharmaceutical, biotechnology and medical device industries across the world. The Company operates through three segments: Clinical Research Services, PAREXEL Consulting Services and PAREXEL Informatics. Its product and service offerings include clinical trials management, data management, epidemiology, health economics/outcomes research, pharmacovigilance, medical communications, clinical pharmacology, patient recruitment, clinical supply and drug logistics, post-marketing surveillance, medical imaging services, electronic data capture systems, clinical trial management systems, Web-based portals, and other product development tools and services.